On June 3, 2026, PyroGenesis Inc. (the “Company”), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, completed a bought deal private placement offering pursuant to the listed issuer financing exemption (the “Offering”) for aggregate gross proceeds of approximately C$4.26 million, including the full exercise of the over-allotment option granted to Research Capital Corporation by the Company.
Under the Offering, 12,514,875 units of the Company (each, a “Unit”) were issued at a price of C$0.34 per Unit. Each Unit consists of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.42 per Common Share until June 3, 2029.
Research Capital Corporation acted as sole underwriter and sole bookrunner in connection with the Offering.
Fasken advised Research Capital Corporation with a team comprised of John Sabetti, Allison Marks and Terence Bernard.
Jurisdiction
- Ontario
